Skip to main content

Table 2 Treatments

From: Primary immunodeficiency-related bronchiectasis in adults: comparison with bronchiectasis of other etiologies in a French reference center

 

Primary immunodeficiencies (n = 20)

Idiopathic and post infectious (n = 39)

Other etiologies (n = 39)

All (n = 98)

P value

Azithromycin

9 (45%)

21 (53.9%)

21 (53.9%)

51 (52%)

0.78

Omalizumab

0*

4 (10.3%)

7 (17.9%)*

11 (11.2%)

0.044

Immunoglobulin substitution

17 (85%)£

1 (2.6%)£

7 (17.9%)£

25 (25.5%)

< 0.001

Inhaled treatments

10 (50%)

26 (66.7%)

27 (69.2%)

63 (70.4%)

0.32

Corticosteroids

6 (30%)

17 (43.6%)

19 (48.7%)

42 (42.9%)

0.39

Long-acting β-agonist

9 (45%)

26 (66.7%)

25 (64.1%)

60 (61.2%)

0.24

Anticholinergic

4 (20%)

7 (17.9%)

9 (23.1%)

20 (20.4%)

0.85

Triple association

2 (10%)

4 (10.3%)

4 (10.3%)

10 (10.2%)

0.99

Statin use

1 (5%)

5 (12.8%)

10 (25.6%)

16 (16.3%)

0.95